Breaking News, Collaborations & Alliances

Isis Earns AstraZeneca Milestone

Phase I study triggers $15M payment

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has initiated a Phase I trial of ISIS-ARRx in patients with cancer, triggering a $15 million milestone payment to Isis Pharmaceuticals. ISIS-ARRx is an antisense drug designed to treat prostate cancer by inhibiting the production of the androgen receptor (AR). AZ plans to develop the drug to treat patients under a variety of settings during the course of prostate cancer treatment, including a single agent and in combination therapy.   “This important milestone takes us another ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters